Communiqués Aridis Pharmaceuticals, Inc.

Actions

ARDS

US0403341045

Recherche biotechnologique et médicale

Marché Fermé - OTC Markets 20:39:59 28/09/2026			Varia. 5j.	Varia. 1 janv.
0,000100 ^USD	0,00%		0,00%	-93,33%

24/06/24	Aridis Pharmaceuticals, Inc. fournit une mise à jour sur les développements récents de l'entreprise	CI
03/11/23	Aridis Pharmaceuticals, Inc. publie ses résultats pour le troisième trimestre et les neuf mois clos le 30 septembre 2023	CI

Communiqués

20/12/24	Aridis Provides Corporate Update	AQ
24/06/24	Aridis Provides Corporate Update	AQ
15/12/23	Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024	AQ
03/11/23	Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Update	AQ
25/08/23	Aridis Pharmaceuticals : Termination of Material Agreement - Form 8-K	PU
02/08/23	Aridis Pharmaceuticals Announces $2 Million Offering	AQ
21/07/23	Aridis Pharmaceuticals : Accelaration/Increase of Financial Obligation - Form 8-K	PU
17/07/23	Aridis Receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301	AQ
12/07/23	Aridis’ AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA’s Qualified Infectious Diseases Product (QIDP) Designation	AQ
20/06/23	Aridis Pharmaceuticals' AR-301 Eligible for Consideration under FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)	AQ
08/06/23	Aridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business Update	AQ
31/05/23	Aridis Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study Design	AQ
25/05/23	Aridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-Q	AQ
09/05/23	ARIDIS PHARMACEUTICALS, INC. : Termination of a Material Definitive Agreement (form 8-K)	AQ
01/05/23	ARIDIS PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits (form 8-K)	AQ
26/04/23	Aridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-K	AQ
21/04/23	ARIDIS PHARMACEUTICALS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ
01/04/23	Aridis Provides Corporate Update	AQ
31/03/23	ARIDIS PHARMACEUTICALS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Change in Directors or Principal Officers (form 8-K)	AQ
29/03/23	Aridis Pharmaceuticals : Termination of Material Agreement - Form 8-K	PU
29/03/23	ARIDIS PHARMACEUTICALS, INC. : Termination of a Material Definitive Agreement (form 8-K)	AQ
22/03/23	ARIDIS PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form 8-K)	AQ
15/03/23	ARIDIS PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
14/03/23	Aridis Pharmaceuticals Announces $2.28 Million Registered Direct Offering of Common Stock	AQ
13/03/23	ARIDIS PHARMACEUTICALS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ